Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-ⅢA non-small-cell lung cancer (PEARLS/…
この記事を読む
一臨床医の勉強のための備忘録です。間違いなどあればご指摘を頂ければ幸いです。
この記事を読む
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-ⅢA non-small-cell lung cancer (PEARLS/…
この記事を読む
Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCL…
この記事を読む
Practical considerations of single-fraction stereotactic ablative radiotherapy to the lung. Kang TM et al.Lung Cancer. 2…
この記事を読む
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: T…
この記事を読む
Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-03…
この記事を読む
Effect of adherence to treatment guidelines on overall survival in elderly non-small-cell lung cancer patients. Lindqvis…
この記事を読む
総説: 肺癌とKRAS―その分子生物学と治療戦略 古賀教将ら肺癌.2022;62:188-199 感想KRASの歴史とその阻害薬に関する日本語の総説です。KRASは変異箇所が限られEGFR遺伝子変異よりはるか前に見つかっています。しかしKR…
この記事を読む
The 2021 Global Lung Cancer Therapy Landscape. Deb D, et al.J Thorac Oncol. 2022 Jul;17(7):931-936.PMID:35489693. Abs of…
この記事を読む
Patterns of Failure and Optimal Treatment Paradigm for Large, Inoperable, Node-Negative Non-small Cell Lung Cancer. Schn…
この記事を読む
High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 mul…